AltruBio key facts
- Developer of first-in-class immune-modulators to target diseases of the immune system.
- It has raised $336.6M across 1 recorded rounds; the latest was Later Stage VC (Series B) ($225.0M) in May 2024.
- Notable investors include RA Capital Management, Blackstone, Cormorant Asset Management, Soleus Capital, CAM Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·Watch AltruBio: the Monday email on marks, rounds and moves
AltruBio funding rounds
1 roundsHow much has AltruBio raised?
AltruBio has raised $337 million in total; 1 of its rounds is on record. The largest on record was a $225 million Series B in May 2024.
AltruBio investors
10 investors are on record for AltruBio, including RA Capital Management, Blackstone, Cormorant Asset Management and Soleus Capital. The Series B in May 2024 drew 7 investors.
About AltruBio
Developer of first-in-class immune-modulators to target diseases of the immune system. The company has clinically validated a first-in-class immune checkpoint regulator mechanism to selectively target unwanted (thymocytes - cells) T-cells with its antibodies, enhancing PSGL-1's natural immune function to downregulate late-stage chronically activated T-cells, enabling a world-class global team to bring a breadth of expertise in immunology and drug development to bring their biologic treatments to patients.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2000
- Employees
- 30
- Website
- altrubio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
AltruBio doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.